Serina Therapeutics reports Cohort 1 observations from SER-252 study
Serina Therapeutics reports cohort 1 observations from its SER-252 registrational study in advanced Parkinson’s disease and advances to cohort 2.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.